Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration.
about
Phosphodiesterase 4-targeted treatments for autoimmune diseasesThe impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers.Apremilast.The pharmacokinetic effect of coadministration of apremilast and methotrexate in individuals with rheumatoid arthritis and psoriatic arthritisApremilast (Otezla): A New Oral Treatment for Adults With Psoriasis and Psoriatic Arthritis.The effects of apremilast on the QTc interval in healthy male volunteers: a formal, thorough QT study.Impact of Renal Impairment on the Pharmacokinetics of Apremilast and Metabolite M12.Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor: A novel treatment option for nurse practitioners treating patients with psoriatic diseaseAltered bone biology in psoriatic arthritis.Apremilast as a treatment for psoriasis.Apremilast for the treatment of psoriatic arthritis.Apremilast: first global approval.Drug safety evaluation of apremilast for treating psoriatic arthritis.Apremilast: A Review in Psoriasis and Psoriatic Arthritis.Apremilast for the treatment of psoriatic arthritis.A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast.Apremilast: A Novel Drug for Treatment of Psoriasis and Psoriatic Arthritis.Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis.Apremilast in the treatment of psoriatic arthritis: a perspective review.Apremilast: A Review in Psoriasis and Psoriatic Arthritis.Apremilast for the management of moderate to severe plaque psoriasis.
P2860
Q21245284-1518934E-9B3D-440F-8CE9-87C502B94EE7Q34548528-7B880549-2928-4EFD-AD1F-BAF943F3A836Q34612877-2774AB36-42AF-4A28-9D5F-20E5D22F0143Q35741946-0253AA55-0283-4983-9B25-36B0A853B241Q35896444-0739560A-2ABF-4FF4-9430-41FCB5FE364CQ37104915-E8A8A413-FD15-4A0A-BB5D-78C3114C2620Q37462071-1D531556-6D52-4931-AC22-9CC6FF59DB39Q37505449-EE782D0E-699F-463D-9D12-EBA85D1198EEQ38010645-6B5C61F7-EB9E-4D1B-8B71-E5FBE136E2B6Q38019980-40C614B5-1E38-4B41-912C-47334D88B96DQ38202205-3C3076F1-DA1E-4AFA-BC50-FA7E69508939Q38209439-2FF08E05-CC93-435A-9E78-B6FB6990D991Q38397948-72DBC643-9788-4251-B47F-57398D10C737Q38556637-9853765A-508A-4E1A-9AAE-B4603E296263Q38616811-B7066FFE-9E9E-4A9B-8116-426D20038BD7Q38675867-2BFE2AF5-4C67-4D5D-9721-AB3837978681Q38702419-6F123B82-E0FE-441E-B346-59F92BB8020AQ38885459-69B4EDD6-6E56-424F-988B-545B9E811FE0Q38932094-AC4CD98A-8F66-4030-8E79-D17A9523F041Q39141679-36B0078B-E792-4C53-9D8F-55DB4AA8CC4EQ39170240-1ED6BB43-5DF9-4F0F-9D72-75D8D1847BE3
P2860
Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Disposition, metabolism and ma ...... following oral administration.
@ast
Disposition, metabolism and ma ...... following oral administration.
@en
Disposition, metabolism and ma ...... following oral administration.
@nl
type
label
Disposition, metabolism and ma ...... following oral administration.
@ast
Disposition, metabolism and ma ...... following oral administration.
@en
Disposition, metabolism and ma ...... following oral administration.
@nl
prefLabel
Disposition, metabolism and ma ...... following oral administration.
@ast
Disposition, metabolism and ma ...... following oral administration.
@en
Disposition, metabolism and ma ...... following oral administration.
@nl
P2093
P2860
P1433
P1476
Disposition, metabolism and ma ...... following oral administration.
@en
P2093
Dennis Heller
Dorota Cedzik
Gondi Kumar
Kei-Lai Fong
Lori Capone
Matthew Hoffmann
Oscar Laskin
Peter Schafer
P2860
P304
P356
10.3109/00498254.2011.604745
P407
P577
2011-08-23T00:00:00Z